The Indian pharmaceutical industry has spent decades earning its reputation as the “pharmacy of the world”. It supplies affordable generic medicines to patients across continents, supports healthcare systems in both developed and emerging economies, and gives India strategic influence far beyond the size of its domestic healthcare market.
But the sector’s next major growth milestone is beginning to look increasingly difficult.
The Pharmaceuticals Export Promotion Council of India, or Pharmexcil, now expects the industry to reach approximately $80 billion to $90 billion by 2030, well below the earlier target of $130 billion.
The market was worth roughly $60 billion in the year ended March 2026, comprising around $31 billion in exports and $29 billion in domestic sales.
This is not merely a missed revenue forecast.
The future of the Indian pharmaceutical industry affects medicine affordability, manufacturing employment, research investment, supply-chain resilience, and access to treatment in more than 200 countries.
India’s pharmaceutical exports have increased from approximately $14 billion in FY2015 to about $31 billion in FY2026. Yet the government’s long-term strategy increasingly recognises that India must move from volume-led pharmaceutical exports to value-led growth.
The central question is not whether Indian pharma will continue to grow. It almost certainly will.
The real question is whether the sector can change the quality of its growth quickly enough.
Key Takeaways
- The Indian pharmaceutical industry is now expected to reach $80–90 billion by 2030 instead of the earlier $130 billion target.
- Reaching $130 billion from a $60 billion base would require annual growth of more than 21%.
- US tariff uncertainty, shipping disruptions, and weaker American demand are affecting pharmaceutical exports from India.
- India remains strong in generic medicines but captures less value from patented drugs, biologics, and complex therapies.
- Missing the target would not mean that Indian pharma is declining. It would indicate that the existing volume-driven model needs to evolve.
Table of Contents
- The $130 billion target and the new reality
- Why the growth arithmetic no longer works
- Seven reasons the target is at risk
- Why missing the target would not mean failure
- What India must do next
- The larger healthcare question
- Frequently asked questions
The $130 Billion Target and the New Reality
For much of the past year, the official India pharma 2030 target remained $130 billion.
Government statements continued to describe the goal as achievable through stronger exports, manufacturing investment, innovation, and rising domestic healthcare demand.
The latest industry assessment is considerably more cautious.
Pharmexcil chairman Namit Joshi told Reuters that US tariff uncertainty, geopolitical instability, and longer shipping routes caused by conflict in the Middle East had weakened the assumptions behind the original target.
He estimated that annual industry growth could remain between 6% and 10% over the next three years before potentially accelerating as higher-value products such as biosimilars and peptides gain scale.
That distinction matters.
The $130 billion figure is now best understood as an industry and policy aspiration. The revised $80–90 billion range is a more conservative operating forecast based on current conditions.
The difference between the two projections is not marginal. Even at the upper end of the revised forecast, the Indian pharmaceutical industry would remain approximately $40 billion below its original ambition.
Why the India Pharmaceutical Industry Growth Arithmetic No Longer Works
The mathematics behind the target helps explain why expectations are being reset.
Starting from an industry value of approximately $60 billion in March 2026:
- Reaching $80 billion by 2030 requires annualised growth of about 7.5%.
- Reaching $90 billion requires annualised growth of roughly 10.7%.
- Reaching $130 billion requires annualised growth of more than 21%.
These calculations are based on the latest $60 billion market estimate.
The first two scenarios broadly align with Pharmexcil’s expectation of 6% to 10% annual growth over the next three years. The $130 billion scenario requires the industry to expand at roughly twice the upper end of that projected range.
This does not make the target mathematically impossible. It does mean that ordinary expansion in generics, domestic formulations, and established export markets will not be enough.
The Indian pharmaceutical industry would need a major acceleration in high-value medicines, research-led businesses, domestic demand, and new export markets, all at the same time.
7 Reasons the Indian Pharmaceutical Industry May Miss $130 Billion
1. The Sector Is Too Exposed to the US Market
The United States is one of the most important destinations for pharmaceutical exports from India.
Indian manufacturers supply nearly half of the generic prescriptions filled in the US, according to the 2022 estimate cited by Reuters.
This relationship has created scale, revenue, and global credibility. It has also created concentration risk.
Indian pharmaceutical shipments to the US declined from approximately $10.5 billion in FY2024–25 to around $9.7 billion in FY2025–26.
Overall pharma exports still increased by 2.13%, supported by demand from Brazil and Europe. However, the decline in American shipments demonstrated how quickly weakness in one market can affect the national growth outlook.
Tariff uncertainty makes the risk more serious.
Reuters reported that imported generic drugs would remain at a zero tariff for two years from August 1, 2026, after which the announced tariff rate would rise sharply.
Whether every element is ultimately implemented exactly as announced, the possibility of a future tariff cliff complicates investment, pricing, and manufacturing decisions for Indian exporters.
Generic medicines are typically a high-volume, low-margin business.
Manufacturers cannot always absorb steep tariffs without increasing prices, withdrawing commercially unviable products, or shifting manufacturing closer to the destination market.
For the Indian pharmaceutical industry, dependence on the US has moved from being only a source of strength to becoming a strategic vulnerability that must be managed.
2. Global Shipping Disruptions Are Eroding Margins
Medicines may occupy less cargo space than industrial products, but pharmaceutical logistics are unusually demanding.
Many medicines require controlled temperatures, validated packaging, strict documentation, and predictable delivery schedules.
When conflict forces vessels to avoid the Red Sea, longer routes do more than increase freight bills. They also extend delivery times, raise insurance costs, lock up working capital, and force manufacturers to maintain additional inventory.
Pharmexcil has identified the West Asian crisis as a threat to exports, production costs, and supply-chain continuity. Reuters has also reported that rerouting cargo is increasing freight costs and transit times for Indian pharmaceutical exporters.
Large manufacturers may be able to absorb some of this pressure. Smaller pharmaceutical companies often cannot.
This matters because the Indian pharma industry includes a substantial number of small and medium-sized manufacturers.
A national growth target can appear achievable on paper while becoming commercially unrealistic for the businesses expected to produce much of the additional volume.
3. India Leads in Volume but Captures Too Little Value
The Indian pharmaceutical industry has become globally indispensable by producing affordable medicines at scale.
Yet volume leadership does not automatically translate into revenue leadership.
Generic drugs are essential to public health, but they are also fiercely competitive. Once a medicine loses patent protection, several manufacturers can enter the market, placing continuous pressure on prices and profit margins.
The most valuable areas of the global pharmaceutical market increasingly include:
- Biologics and biosimilars
- Peptide-based medicines
- Complex injectables
- Specialty medicines
- Novel drug-delivery systems
- Patented therapies
- Contract research and development
- Advanced pharmaceutical manufacturing
India has capabilities in several of these areas, but not yet at the scale required to transform the industry’s overall revenue base.
This is the deepest structural issue behind the target.
India does not simply need to sell more medicines. It needs to earn more from its scientific expertise, complex manufacturing capabilities, regulatory knowledge, and intellectual property.
The government has acknowledged this challenge by emphasising a shift from volume-led exports to value-led exports and setting an ambition of reaching $50 billion in pharmaceutical exports by 2030.
4. India’s Innovation Pipeline Is Not Yet Commercial Enough
India has strong chemistry talent, an extensive scientific workforce, and a highly successful generic-drug ecosystem.
But discovering and commercialising an original medicine requires a very different business model.
Innovative drug development involves early scientific research, preclinical testing, clinical trials, regulatory submissions, manufacturing scale-up, and years of uncertain investment.
A large proportion of promising drug candidates fail before reaching patients.
The ₹5,000 crore Promotion of Research and Innovation in Pharma MedTech scheme is designed to strengthen this ecosystem. The programme supports centres of excellence and industry research projects across the path from early research to product development and commercialisation.
The initiative is strategically important, but funding announcements alone do not create globally successful medicines.
India also needs:
- Stronger university-industry partnerships
- More patient, long-term investment capital
- Better technology-transfer systems
- Experienced clinical-development teams
- Faster pathways from laboratories to commercial manufacturing
- A predictable regulatory environment that protects patient safety
The India pharmaceutical industry will struggle to achieve a major increase in value until more Indian research becomes commercially viable intellectual property.
5. Quality Reform Is Necessary, but Expensive
Trust is one of the pharmaceutical sector’s most valuable assets.
A medicine that is inexpensive but unreliable has no sustainable place in healthcare.
India has intensified its enforcement of manufacturing standards. Since December 2022, the Central Drugs Standard Control Organisation and state regulators have conducted risk-based inspections of more than 960 premises.
Authorities took more than 860 actions, including show-cause notices, stop-production orders, licence suspensions and cancellations.
This enforcement is essential for patient safety and international confidence. It should not be interpreted only as negative news for the industry.
However, regulatory compliance carries a high financial cost.
Manufacturers may need to invest in:
- Modern production equipment
- Contamination-control systems
- Validated cleaning processes
- Digital manufacturing records
- Stronger testing laboratories
- Workforce training
- Advanced quality-management systems
Large pharmaceutical businesses can distribute these costs across global operations. Smaller manufacturers may find the transition far more difficult.
In the short term, tighter standards may slow capacity growth or force weaker facilities to exit the market.
In the long term, stronger standards can make the Indian pharmaceutical industry more trusted, productive, and globally competitive.
The key is to recognise quality expenditure as growth infrastructure and not merely as a regulatory burden.
6. Dependence on Imported Drug Ingredients Remains a Weak Point
India is a major exporter of finished medicines, yet parts of its upstream pharmaceutical supply chain remain dependent on imported active pharmaceutical ingredients, key starting materials, and drug intermediates.
In FY2024–25, India imported approximately 200 categories of APIs, bulk drugs, and intermediates worth around $4.35 billion.
The government has warned that single-source vulnerabilities can threaten pharmaceutical security and supply continuity.
Policy efforts are beginning to expand domestic capacity.
Under the production-linked incentive programme for bulk drugs, manufacturing capacity of approximately 56,800 metric tonnes a year had been established for 28 of 41 identified critical products by March 2026.
Three bulk-drug parks have also been approved in Andhra Pradesh, Gujarat, and Himachal Pradesh.
But pharmaceutical self-reliance cannot be achieved by manufacturing ingredients domestically at any cost.
Indian APIs must also be commercially competitive, environmentally sustainable, and consistently high quality.
Otherwise, formulation companies may face higher input costs that weaken export margins and increase pressure on medicine affordability.
For the Indian pharmaceutical industry, supply-chain resilience and cost competitiveness must advance together.
7. Domestic Growth Cannot Fully Offset Export Weakness
The Indian pharmaceutical market has powerful long-term demand drivers.
The country’s healthcare needs are expanding, while demand for chronic-disease treatment, diagnostics, hospital services, and preventive care is becoming more significant.
However, domestic pharmaceutical growth has its own constraints.
India remains a highly price-sensitive healthcare market. Treatment decisions are often influenced by household affordability, while intense competition in branded generics limits how quickly manufacturers can increase revenue.
Growth in medicine consumption does not always produce an equal increase in industry value.
There is also an ethical tension at the centre of the sector’s domestic strategy.
The Indian pharmaceutical industry must become more innovative and profitable without making essential treatment less affordable.
That balance becomes more difficult when research expenses, quality-compliance costs, and manufacturing investments are all rising.
Domestic demand can provide stability. It cannot, by itself, close a $40 billion to $50 billion gap by 2030.
Why Missing the Target Would Not Mean the Indian Pharma Industry Is Failing
A lower 2030 valuation should not be confused with industrial decline.
Pharmaceutical exports from India have more than doubled over the past decade, reaching approximately $31.11 billion in FY2025–26, according to Pharmexcil.
Indian medicines now reach patients in more than 200 countries.
The sector continues to benefit from durable advantages, including:
- A large pool of scientific and technical talent
- Decades of experience in regulated export markets
- Competitive manufacturing costs
- Strong generic-drug and vaccine capabilities
- A growing domestic healthcare market
- Expanding expertise in biosimilars, peptides, and complex products
The revised forecast should therefore be treated as a strategic warning rather than a prediction of decline.
The model that made India the pharmacy of the world may not be sufficient to make it one of the world’s most valuable pharmaceutical economies.
That distinction should shape the policy response.
Chasing the headline number through low-margin volume alone could weaken quality, compress profitability, and leave manufacturers more exposed to global disruptions.
A smaller industry with stronger margins, better compliance, more intellectual property and more resilient supply chains may ultimately be healthier than a larger industry built on fragile assumptions.
What the Indian Pharmaceutical Industry Must Do Next
Diversify Export Markets Before the Next Shock
Brazil and Europe helped support export performance when shipments to the US declined.
India should deepen market access across Latin America, Africa, Southeast Asia, the Middle East and other regulated and semi-regulated markets.
Diversification should not begin only when the American market becomes difficult. It must be built into the national pharmaceutical export strategy.
Companies will need local regulatory expertise, distribution partnerships, country-specific portfolios and stronger recognition among healthcare institutions.
Scale Biosimilars and Complex Medicines Faster
Biosimilars, peptides, complex injectables, and specialty medicines offer a pathway towards higher revenue without abandoning India’s commitment to affordability.
These products are harder to develop, manufacture, and regulate than conventional generics.
That difficulty creates stronger barriers to entry and can support better commercial margins.
Public funding can accelerate development, but success will depend on Indian companies building clinical, regulatory and manufacturing capabilities that meet the highest international standards.
Turn Quality Compliance Into a Commercial Advantage
India should not treat quality reform only as damage control.
A strong regulatory system can become an export asset.
Transparent enforcement, reliable laboratory testing, digital inspection systems, and alignment with international manufacturing standards can improve market access and reduce the reputational discount sometimes applied to Indian manufacturers.
The objective should be clear: medicines made in India must be associated not only with affordability, but also with unquestioned reliability.
Give Pharmaceutical MSMEs a Viable Upgrade Path
Smaller pharmaceutical businesses need more than compliance deadlines.
They need affordable financing, shared testing facilities, technical support, digital compliance tools, and cluster-based infrastructure.
Without such assistance, quality reform could create excessive consolidation or remove manufacturers that possess technical capability but lack sufficient capital.
A carefully managed transition would protect employment and manufacturing capacity while raising standards across the industry.
Build a Stronger Bridge From Research to Revenue
India’s research institutions produce significant scientific knowledge, but commercial translation remains uneven.
The country needs better licensing frameworks, translational research funding, technology-transfer offices and partnerships connecting universities, hospitals, startups, and established drugmakers.
The success of research policy should not be measured only by the number of grants issued.
It should be measured by how many discoveries move from laboratories into clinical development, regulatory approval, manufacturing, and global markets.
Reduce API Dependence Strategically
Domestic manufacturing incentives should prioritise ingredients that are medically critical or excessively dependent on a single international source.
However, new capacity must also remain commercially sustainable.
Energy costs, environmental approvals, shared infrastructure, and production scale will determine whether domestic API manufacturing remains viable after government incentives decline.
Measure Progress With Better Data
One reason the $130 billion debate can become confusing is that public statements do not always define the pharmaceutical market in exactly the same way.
Policymakers should publish a consistent industry scorecard covering:
- Domestic pharmaceutical revenue
- Export revenue
- Share of high-value products
- Research and development investment
- Biosimilar and novel-drug approvals
- API import concentration
- Manufacturing compliance
- Export-market diversification
- Industry profitability
- Patient access and affordability
Clear milestones would turn a broad ambition into an accountable industrial strategy.
The Bigger Healthcare Question Behind the $130 Billion Target
The debate over the India pharma 2030 target is not only about economic size.
India’s pharmaceutical model has helped reduce medicine prices and expand treatment access around the world.
Any shift towards higher-value products must protect that public-health contribution.
India should not abandon generic medicines in pursuit of prestige. Nor should policymakers assume that low-cost manufacturing alone can finance the next generation of research, quality reform, and supply-chain resilience.
The real opportunity is to do both.
India can remain a major source of affordable essential medicines while becoming more competitive in biologics, complex generics, drug discovery, and advanced manufacturing.
That requires a more sophisticated definition of success—one that measures patient access, manufacturing quality, supply resilience, and innovation alongside revenue.
Conclusion: The Target May Be Missed, but the Opportunity Is Larger
The Indian pharmaceutical industry may not reach $130 billion by 2030.
Based on current growth expectations, an outcome between $80 billion and $90 billion appears more realistic.
But the target itself is not the most important issue.
The deeper challenge is whether India can move from a predominantly volume-driven model to one that captures more value from research, complex manufacturing, quality, and intellectual property—without sacrificing affordable access to treatment.
Tariff uncertainty, shipping disruptions, and weaker US shipments have exposed the vulnerabilities of the existing model.
Quality enforcement, research funding, and API-manufacturing incentives demonstrate that the transition has begun.
What remains uncertain is whether it can happen quickly enough.
India became the pharmacy of the world by making medicines accessible. Its next task is to become one of the world’s most trusted and innovative pharmaceutical centres.
Missing one financial milestone would not erase that opportunity.
Failing to modernise the industry’s growth model might.
Stay connected with Business Herald for the latest business news, insights, and updates.
Follow us on Facebook, Instagram, LinkedIn, and YouTube.
Join our growing community on WhatsApp and Telegram for real-time updates delivered directly to you.
